Drugs / Emibetuzumab
Trials 6
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT01602289 | Jun 2012 → Aug 2014 | lymphoma, non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01287546 | Apr 2010 → Jan 2015 | — | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02082210 | Mar 2014 → Dec 2017 | cancer of unknown primary site, gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, hepatocellular carcinoma +2 | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 23 trials | ||||||
| Phase 2 | NCT01897480 | Aug 2013 → Mar 2016 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01900652 | Aug 2013 → Feb 2015 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT01874938 | Aug 2013 → Aug 2014 | gastric cancer | Eli Lilly and Company | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2013-04-10 | Eli Lilly and Company | Results Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting lilly.com ↗
These findings indicate that LY2875358 has a different mechanism of action from the 5D5 MET antibody and may be a promising therapy for treatment of patients whose tumors are driven by HGF-dependent and HGF-independent MET activation. |
| 2012-04-02 | Eli Lilly and Company | Results Lilly Targets Faulty c-MET Receptor in Cancer Research Studies Presented Today at AACR Meeting lilly.com ↗
Eli Lilly and Company (NYSE: LLY) today announced results of three preclinical studies focused on c-MET, a receptor tyrosine kinase that, when it functions normally, plays a key role in transmitting signals within a cell. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2013-04-10 | Eli Lilly and Company | Lilly Debuts Early Oncology Pipeline Data At AACR Annual Meeting lilly.com ↗ |
| 2012-04-02 | Eli Lilly and Company | Lilly Targets Faulty c-MET Receptor in Cancer Research Studies Presented Today at AACR Meeting lilly.com ↗ |
Evidence & citations 8 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Emibetuzumab | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01900652 ↗ |
| Known as | C-8H241 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301578 ↗ |
| Known as | LA480 | ChEMBL registry synonym — accepted as the source's own label CHEMBL3301578 ↗ |
| Known as | LY2875358 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01874938 ↗ |
| Action | Inhibit | “Hepatocyte growth factor receptor inhibitor” CHEMBL3301578 ↗ |
| Modality | Monoclonal antibody | — CHEMBL3301578 ↗ |
| Route | Intravenous | “administered intravenously (IV)” NCT01287546 ↗ |
| Target | MET | “Hepatocyte growth factor receptor inhibitor” CHEMBL3301578 ↗ |